Rheumatoid arthritis patients often cycle through multiple drugs before finding relief, due to insurer and pharmacy benefit manager influence. The best-selling drug in history, Humira, is typically the first prescription offered, despite only providing significant relief to half of patients. A new blood test called PrismRA has the potential to revolutionize treatment by identifying patients unlikely to respond to TNF inhibitor drugs, but its high cost and lack of insurance coverage has been a barrier. However, as more insurers begin to reimburse for the test, it has the potential to significantly reduce the trial-and-error period for patients, who often experience anxiety and frustration throughout the process.
Source link
A New Test Could Save Arthritis Patients Time, Money, and Pain. But Will It Be Used?
